Legend Biotech/$LEGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Legend Biotech
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
Ticker
$LEGN
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
2,700
ISIN
US52490G1022
Website
Legend Biotech Metrics
BasicAdvanced
$6.2B
-
-$1.19
0.20
-
Price and volume
Market cap
$6.2B
Beta
0.2
52-week high
$60.87
52-week low
$27.34
Average daily volume
2.1M
Financial strength
Current ratio
5.2
Quick ratio
5.002
Long term debt to equity
35.123
Total debt to equity
35.648
Interest coverage (TTM)
-11.22%
Profitability
EBITDA (TTM)
-228.34
Gross margin (TTM)
8.60%
Net profit margin (TTM)
-29.95%
Operating margin (TTM)
-32.67%
Effective tax rate (TTM)
-10.47%
Revenue per employee (TTM)
$270,000
Management effectiveness
Return on assets (TTM)
-8.77%
Return on equity (TTM)
-20.00%
Valuation
Price to revenue (TTM)
8.413
Price to book
6.04
Price to tangible book (TTM)
6.06
Price to free cash flow (TTM)
-22.431
Free cash flow yield (TTM)
-4.46%
Free cash flow per share (TTM)
-149.04%
Growth
Revenue change (TTM)
112.46%
Earnings per share change (TTM)
-53.95%
3-year revenue growth (CAGR)
83.13%
3-year earnings per share growth (CAGR)
-20.52%
What the Analysts think about Legend Biotech
Analyst ratings (Buy, Hold, Sell) for Legend Biotech stock.
Bulls say / Bears say
Legend Biotech's CARVYKTI® achieved net trade sales of approximately $963 million in 2024, reflecting strong market adoption and revenue growth. (biospace.com)
The company maintains a robust financial position with $1.1 billion in cash and equivalents as of December 31, 2024, providing a financial runway into the second quarter of fiscal year 2026. (biospace.com)
Legend Biotech has expanded its manufacturing capabilities by initiating commercial production of CARVYKTI® at a Novartis facility, potentially increasing supply to meet growing demand. (biospace.com)
Morgan Stanley reduced its price target for Legend Biotech to $82 from $85, citing a revised 2024 sales forecast for CARVYKTI® from over $1 billion to $850 million. (investing.com)
The company reported a net loss of $177.0 million for the full year 2024, despite increased revenues, indicating ongoing profitability challenges. (simplywall.st)
Legend Biotech is undergoing financial restructuring due to Genscript Biotech's decision to deconsolidate its financial statements, which may impact financial reporting and market perception. (nasdaq.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2025.
Legend Biotech Financial Performance
Revenues and expenses
Legend Biotech Earnings Performance
Company profitability
Legend Biotech News
AllArticlesVideos
Legend Biotech Corporation INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Legend Biotech Corporation (LEGN)
Accesswire·2 weeks ago
LEGN STOCK ALERT: Levi & Korsinsky Notifies Legend Biotech Corporation Investors of an Ongoing Investigation
Accesswire·2 weeks ago
Shareholders That Lost Money on Legend Biotech Corporation (LEGN) Should Contact Levi & Korsinsky about Securities Fraud Investigation - LEGN
Accesswire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Legend Biotech stock?
Legend Biotech (LEGN) has a market cap of $6.2B as of June 26, 2025.
What is the P/E ratio for Legend Biotech stock?
The price to earnings (P/E) ratio for Legend Biotech (LEGN) stock is 0 as of June 26, 2025.
Does Legend Biotech stock pay dividends?
No, Legend Biotech (LEGN) stock does not pay dividends to its shareholders as of June 26, 2025.
When is the next Legend Biotech dividend payment date?
Legend Biotech (LEGN) stock does not pay dividends to its shareholders.
What is the beta indicator for Legend Biotech?
Legend Biotech (LEGN) has a beta rating of 0.2. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.